These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2900947)

  • 41. Acute graft-versus-host disease in allogeneic marrow transplantation.
    Parker N; Cohen T
    Nurs Clin North Am; 1983 Sep; 18(3):569-77. PubMed ID: 6351023
    [No Abstract]   [Full Text] [Related]  

  • 42. Phases in a drug's use.
    Duffin J
    CMAJ; 1992 Sep; 147(5):588. PubMed ID: 1521204
    [No Abstract]   [Full Text] [Related]  

  • 43. [Treatment with thalidomide and production of tumor necrosis factor alpha].
    Pizarro A; Pinilla J; García-Tobaruela A
    Med Clin (Barc); 1993 Jun; 101(4):158. PubMed ID: 8355553
    [No Abstract]   [Full Text] [Related]  

  • 44. [-Rejection of an allogeneic bone marrow graft following successful treatment of severe graft-versus-host disease (GVHD)].
    Sugimori N; Nakao S; Takamatsu H; Takami A; Ueda M; Shiobara S; Matsuda T
    Rinsho Ketsueki; 1996 Feb; 37(2):134-8. PubMed ID: 8852031
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 15-Deoxyspergualin controls cyclosporin- and steroid-resistant intestinal acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Kasai M; Higa T; Naohara T; Masauzi N; Watanabe M; Matsuura A; Ohizumi H; Tanaka J; Morii K; Kiyama Y
    Bone Marrow Transplant; 1994 Aug; 14(2):315-7. PubMed ID: 7994248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506.
    Cooper MH; Markus PM; Cai X; Starzl TE; Fung JJ
    Transplant Proc; 1991 Dec; 23(6):3238-9. PubMed ID: 1721421
    [No Abstract]   [Full Text] [Related]  

  • 47. Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model.
    Vogelsang GB; Wells MC; Santos GW; Chen TL; Hess AD
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):226-8. PubMed ID: 3284069
    [No Abstract]   [Full Text] [Related]  

  • 48. Orthoclone OKT3 for graft failure after allogeneic bone marrow transplantation: a case report.
    Yen CC; Chen PM; Chiou TJ; Hsieh RK
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Feb; 59(2):126-31. PubMed ID: 9175303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A cautious comeback for thalidomide.
    Harv Health Lett; 1998 Feb; 23(4):4-5. PubMed ID: 9516304
    [No Abstract]   [Full Text] [Related]  

  • 50. High-dose methylprednisolone is effective in the management of acute graft-versus-host disease in severe combined immune deficiency.
    Somech R; Kavadas FD; Atkinson A; Grunebaum E; Roifman CM
    J Allergy Clin Immunol; 2008 Dec; 122(6):1215-6. PubMed ID: 18672279
    [No Abstract]   [Full Text] [Related]  

  • 51. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thalidomide: new preparation. For well-defined indications.
    Prescrire Int; 1998 Oct; 7(37):131-4. PubMed ID: 10848043
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Severe acute graft-versus-host disease occurring after syngeneic BMT for AML in a patient not given prior cyclosporin A therapy.
    Hwang WY; Goh YT; Tan CH; How GF; Tan HC
    Bone Marrow Transplant; 2000 Jan; 25(2):205-7. PubMed ID: 10673682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thalidomide for graft-versus-host disease.
    Vogelsang GB; Santos GW; Colvin OM; Chen T
    Lancet; 1988 Apr; 1(8589):827. PubMed ID: 2895345
    [No Abstract]   [Full Text] [Related]  

  • 55. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
    Kumar S; Wolf RC; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2002 Aug; 30(3):161-5. PubMed ID: 12189534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thalidomide: dermatological indications, mechanisms of action and side-effects.
    Wu JJ; Huang DB; Pang KR; Hsu S; Tyring SK
    Br J Dermatol; 2005 Aug; 153(2):254-73. PubMed ID: 16086735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation.
    Tzakis AG; Abu-Elmagd K; Fung JJ; Bloom EJ; Nour B; Greif F; Starzl TE
    Transplant Proc; 1991 Dec; 23(6):3225-7. PubMed ID: 1721416
    [No Abstract]   [Full Text] [Related]  

  • 60. Review of thalidomide use in the pediatric population.
    Yang CS; Kim C; Antaya RJ
    J Am Acad Dermatol; 2015 Apr; 72(4):703-11. PubMed ID: 25617013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.